ESMO25: Following the science to a cure, with Nancy Ghattas

At ESMO this year, AstraZeneca presented final overall survival results from the MATTERHORN Phase III Trial for patients with resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

To explore this data further, pharmaphorum spoke with Nancy Ghattas, Vice President, US Oncology Commercial Franchise Head of Immuno Oncology (GI, Lung, GYN, GU), at AstraZeneca.

Ghattas describes the landscape of unmet need for these cancers, how the data builds upon AstraZeneca’s commitment to moving novel treatments into early-stage cancers where cure is possible, and the wider ESMO Congress.

Watch this and other conversations from ESMO 2025 here.